Date and TimeTitle
Oct 20, 2020
9:10am - 9:50am (East-Indiana)
Keynote - From Precision Medicine to Precision Public Health: Opportunities and Challenges

Advances in genomics and precision health technologies are changing the practice of medicine and public health. In this talk, I will explore the historical evolution and impact of genomics and related technologies on population health. I will explore the public health response to genomics and precision health technologies, using specific examples from CDC and public health programs to illustrate the current opportunities and challenges of new technologies in improving population health and preventing disease.

Oct 20, 2020
9:55am - 10:15am (East-Indiana)
The State of the Evidence for Using Genetics in Population Screening

• CDC Tier 1 vs ACMG59
• The importance of considering disease prevalence on PPV
• Methods for avoiding false positives in setting of low disease prevalence

Oct 20, 2020
10:25am - 10:56am (Eastern)
Keynote: The Role of the Environment in Precision Medicine

The Human Genome Project has provided the transformative genome analysis tools that are helping to usher in a new era of Precision Medicine.  The recently launched International Common Disease Alliance (ICDA) is working to define a new set of objectives that aim to bring greater cooperation across the global biomedical community and to enable a new research platform called Maps to Mechanisms to Medicine program (M2M2M). The objectives of this new program are to better understand that complex traits associated with common disease, decipher disease mechanisms, and build strong programs that will systematically bring complex traits and disease mechanisms into the clinic and public health communities. Through the Personalized Environment and Genetics Study (PEGS), NIEHS is collecting data on exposures in participants from NC that will be combined with genetic analysis and information from electronic health records on common disease phenotypes. Integrating environmental exposures data and environmentally-mediated epigenomic changes will ultimately provide a more complete data platform that can be applied to enable the emerging new programs in Precision Medicine.     

Oct 20, 2020
10:56am - 11:15am (Eastern)
Delivering Precision Medicine to the Patients in Community-Based Populations
Oct 20, 2020
11:15am - 12:15pm (Eastern)
Using Data to Enable Precision Health Programs
Oct 21, 2020
9:05am - 9:35am (Eastern)
Keynote - Precision Health Policy
Oct 21, 2020
9:40am - 10:00am (Eastern)
Policy Challenges and Opportunities with Precision Health Innovation
Oct 21, 2020
10:05am - 10:25am (Eastern)
Using Mobile Health Technologies to Detect and Monitor Illness including COVID-19

Recent technological advancements make it possible to closely and continuously monitor individuals on multiple scales in real time while also incorporating genetic, environmental, and lifestyle information. We are collecting and using this multi-scale biomedical data to gain a more precise understanding of health and disease at molecular and physiological levels and developing actionable, predictive health models for improving cardiometabolic outcomes. We are simultaneously developing tools for the digital health community, including the Digital Biomarker Discovery Pipeline (DBDP), to facilitate the use of mobile device data in healthcare. Most recently, we have focused on applying machine learning methods to a diverse set of wearable sensor and clinical data to detect and monitor COVID-19 infection, including detecting early signs of infection, susceptibility to infection, and predicting infection trajectories.


Oct 21, 2020
10:35am - 11:03am (East-Indiana)
Precision 20 - Critical Success Factors for Addressing the Next Generation of Precision Medicine
Oct 21, 2020
11:15am - 12:15pm (Eastern)
The Young Investigators

One-year cost-effectiveness of CYP2C19-guided de-escalation and escalation of P2Y12 inhibitors in Veterans with acute coronary syndromes undergoing percutaneous coronary intervention –

Olivia Dong, PhD, MPH, Duke University


Clinically relevant phenotypes of type 1 diabetes (T1D): proof of principle for precision health in chronic disease and next steps for translation

Anna Kahkoska PhD UNC


Immuno-Reactive Cancer Organoid Models to Examine Microbiome Metabolite Effects on Immune Checkpoint Blockade Efficacy

Ethan Shelkey Graduate Student, Wake Forest


Personalized Risk Predictions of the Microvascular Complications of Diabetes using the SMART Framework

Breanna Swan, MS, Graduate Student, NCSU